HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- benzyl- 1- (3- iodobenzylsulfonyl)piperidine

a sigma receptor ligand; structure in first source

Also Known As:

4-B-(125I)-IBSP; 4-B-IBSP; 4-benzyl-1-(3-(125I)-iodobenzylsulfonyl)piperidine

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - 4-benzyl-1-(3-iodobenzylsulfonyl)piperidine: 1
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - 4-benzyl-1-(3-iodobenzylsulfonyl)piperidine: 1
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - 4-benzyl-1-(3-iodobenzylsulfonyl)piperidine: 1

Experts

1.	Alirezapour, Behrouz: 1 article (05/2017)
2.	Baghery, Maryam Keshavarz: 1 article (05/2017)
3.	Charkhlooie, Ghorban Ali: 1 article (05/2017)
4.	Khorouti, Amir: 1 article (05/2017)
5.	Sadeghzadeh, Masoud: 1 article (05/2017)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2017 - "Biodistribution experiments of 4-B-[125I]IBSP in breast adenocarcinoma tumor-bearing BALB/c mice showed a relatively high tumor uptake at 30 min p.i. (4.13 ± 0.95) that reaches to 1.57 ± 0.24 even after 240 min p.i. A pre-injection of 4-B-IBSP and haloperidol with 4-B-[125I]IBSP resulted in 36-57% decrease in activity in the tumor, liver, and brain at 60 min p.i. The high affinity of 4-B-[125I]IBSP to σ receptor-binding sites, its relatively high uptake, and preferential retention in the tumor as well as an increasing trend observed in the tumor to blood and in the tumor to muscle ratios suggests that an iodine-123 labeled counterpart, 4-B-[123I]IBSP, would be a promising σ radioligand for pursuing further studies to assess its potential for breast tumors imaging with SPECT."
2.	Breast Neoplasms (Breast Cancer) 05/01/2017 - "Biodistribution experiments of 4-B-[125I]IBSP in breast adenocarcinoma tumor-bearing BALB/c mice showed a relatively high tumor uptake at 30 min p.i. (4.13 ± 0.95) that reaches to 1.57 ± 0.24 even after 240 min p.i. A pre-injection of 4-B-IBSP and haloperidol with 4-B-[125I]IBSP resulted in 36-57% decrease in activity in the tumor, liver, and brain at 60 min p.i. The high affinity of 4-B-[125I]IBSP to σ receptor-binding sites, its relatively high uptake, and preferential retention in the tumor as well as an increasing trend observed in the tumor to blood and in the tumor to muscle ratios suggests that an iodine-123 labeled counterpart, 4-B-[123I]IBSP, would be a promising σ radioligand for pursuing further studies to assess its potential for breast tumors imaging with SPECT."
3.	Adenocarcinoma 05/01/2017 - "Biodistribution experiments of 4-B-[125I]IBSP in breast adenocarcinoma tumor-bearing BALB/c mice showed a relatively high tumor uptake at 30 min p.i. (4.13 ± 0.95) that reaches to 1.57 ± 0.24 even after 240 min p.i. A pre-injection of 4-B-IBSP and haloperidol with 4-B-[125I]IBSP resulted in 36-57% decrease in activity in the tumor, liver, and brain at 60 min p.i. The high affinity of 4-B-[125I]IBSP to σ receptor-binding sites, its relatively high uptake, and preferential retention in the tumor as well as an increasing trend observed in the tumor to blood and in the tumor to muscle ratios suggests that an iodine-123 labeled counterpart, 4-B-[123I]IBSP, would be a promising σ radioligand for pursuing further studies to assess its potential for breast tumors imaging with SPECT."

Related Drugs and Biologics

1.	Haloperidol (Haldol)
2.	Iodine-123